Amy Cravey

Assisted the Jefferson County UniServ staff to recruit, retain, and reclaim members, promoted the success of the "10 by 10" membership campaign. Served as a positive representative of the association, forming a personal link between the association and members.

Launched and promoted Jornay PM, the first and only ADHD medication dosed in the evening. Accountable for driving sales in the ADHD market calling on a variety of targeted specialists including Internal Medicine, Neurology, Pediatrics and Psychiatry to increase overall market share and product awareness.

• Ranked 30 out of 400 Representatives 3rd quarter 2019.
• Selected to represent the company at 2 society meetings.
• February 2020 "Drive for Five" Contest Winner for the Southeast Region.
• February 2020 "Be Great for Eight" Contest Winner for the Southeast Region.
• Verix Champion for the District.

Individually established new territory for Abbott (formerly Alere) Medication Monitoring services in Alabama, Georgia and Mississippi. Accountable for driving sales in the medication monitoring market calling on physicians, laboratory director's, CEO's, CFO's and hospitals. Developed and executed plans to meet and exceed sales goals and metrics. Educated physicians and staff about the clinical and regulatory importance of Medication Monitoring.

• Grew territory from $0 to $1.179m annual revenue.
• Developed 100% new business from a zero-base portfolio using traditional sales techniques (e.g. cold-calling, networking).
• Hired and trained 20 Field Service Representatives.
• Achieved Top 5% performance for customer retention and growth 2010-2018.
• # 3 in revenue for 2017 and 2018.
• Field Advisory Board Member 2013 and 2014.
• Earned Rookie of the Year Award for 2011.

Launched and Promoted (Actiq/Fentora/Amrix) to a variety of specialties including Anesthesiology, Neurology, Oncology, Orthopedic Surgeons, Physical Medicine and Rehab, Psychiatry and Rheumatology. Developed strong client relationships and conducted clinical-based product presentations to increase overall market share and product awareness.

• Top 20% for 3rd quarter in 2009.
• Top 10% overall in 2008.
• Top District Representative for 1st quarter in 2008.
• Top Representative for 2nd quarter in 2007.
• Increased Fentora growth 42% in 1st quarter of 2007.
• Increased rankings 76 positions from 92/100 to 17/100 in 2006.
• Top District Representative for overall performance in 2nd and 3rd quarter of 2006.

Responsible for launching and promoting Vytorin and Zetia to a variety of specialties including Cardiology, Endocrinology, Gastroenterology and Internal Medicine. Worked effectively with Merck counterparts assuring product pull-through to expand market presence. Responsible for launching and promoting Clarinex, Nasonex and Tequin to a variety of specialties including ENT's, Infectious Disease, Internal Medicine, Pharmacist, Pulmonology and Urology. Maintained ongoing responsibility with other territory representatives, which required proficient application of organizational skills, communication abilities, flexibility, and extensive product knowledge. Evaluated sales performance and refined marketing plans to maximize effectiveness. Ensured all client communications aligned with product FDA labeling. Interacted with key account contacts to maintain relationships, uncover needs and stay updated on initiatives and goals.

• Achieved 145% of prescription goal through third quarter in 2005.
• Top 10% of Zetia in 2004.
• Top 10% of Vytorin in 2004.
• Top 10% of Zetia in 2003.
• Top 7% of Tequin in 2002.
• Top 10% of Clarinex in 2002.

Responsible for promoting Claritin, Diprolene and Elocon to a variety of specialties including Pediatric, Family Medicine, Allergy and ENT's.

Performed all sales related functions for territory, billing in excess of $1.6 million annually.

• Named Number 1 in Produce Sales for Mobile District.
• Named Number 4 in Sales of Sysco Brands out of total sales force of 96.
• Recognized as Top Sales Representative for Opening New Accounts in the Mobile Area.
• Increased sales volume from $759,000 to $1,639,000 within three years.